SOLIGENIX INC (SNGX)

Company Profile

Soligenix Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Princeton, New Jersey and currently employs 13 full-time employees. Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.

Company Info

SOLIGENIX INC

29 Emmons Drive, Suite B-10

Princeton NEW JERSEY 08540

P: 16095388200

CEO: Christopher J. Schaber

Employees: 14

Website: https://www.soligenix.com/